Hey readers! Here is something that might surprise you: the biggest news in this issue is not that a GLP-1 drug helped people lose weight. It is how clearly the weight and insulin numbers moved while the glucose numbers stayed stubborn. That gap is worth understanding, so let's start there.
💉 Tirzepatide meets type 1, for the first time in a controlled trial
Tirzepatide in Type 1 Diabetes: The Phase 2 Trial Results covers the first published placebo-controlled phase 2 trial of tirzepatide in adults with type 1 diabetes, a 12-week study of 24 participants with a BMI above 30 taking up to 5 mg weekly.
- WeightLossRankings.org
The headline results are striking for their size: a placebo-adjusted weight loss of 8.7 kg and a 35.1% reduction in total daily insulin dose relative to placebo. For people carrying extra weight on top of type 1, who often fight insulin-driven hunger and rising doses, that combination speaks directly to a daily frustration.
Tirzepatide beat placebo for weight loss in the first published placebo-controlled trial in type 1 diabetes: adults lost 8.7 kg more than the placebo group over 12 weeks (95% CI -12.0 to -5.5), and their total daily insulin dose fell 35.1% relative to placebo.
Here is where compassion and clear-eyed reading meet. The glucose story was far softer: HbA1c dropped just 0.4% versus placebo and was borderline (P = 0.05), while CGM time in range did not differ significantly (P = 0.17). So this is a weight-and-insulin signal more than a glucose-control one. And with only 24 people over 12 weeks, as the authors stress, a trial this small cannot rule out rare but serious risks.
With 24 participants over 12 weeks, zero events cannot rule out a real risk.
No ketoacidosis or severe hypoglycemia occurred in either arm, which is reassuring but not definitive. The dose was capped at 5 mg, injections happened in a supervised research setting, and the authors are explicit that larger phase 3 work is needed before anyone draws firm conclusions.
🧪 A second incretin candidate, same tension
Tirzepatide is not the only incretin being tested in type 1. Acmopatide Shows Promising Glycemic and Weight Control in Overweight Adults with Type 1 Diabetes reports a 16-week, double-blind, placebo-controlled phase 2 trial of acmopatide, a GLP-1/GIP receptor agonist, in 111 overweight or obese adults with type 1 diabetes.
- MedXY
Acmopatide pushed HbA1c down 0.4% to 0.6% versus 0.3% on placebo, and at the 4.1 mg dose, 55.6% of participants reached HbA1c below 7.0% versus 33.3% on placebo. Weight fell about 3.3% to 6.7% while the placebo group gained roughly 0.3%, and insulin needs dropped beyond placebo. A complementary write-up in GLP-1 drugs may open a new path to weight loss for adults with type 1 diabetes frames the same results published Oct. 28, 2026 in Diabetes Care.
Importantly, no episodes of diabetic ketoacidosis or severe hypoglycemia were reported, which addresses a major safety concern with incretin-based therapies in T1D.
Why highlight both trials together? They are not head-to-head, and their designs differ, but they point the same direction: incretin drugs can reliably trim weight and insulin in type 1, while the glucose benefit is more modest and dose-dependent. That is a useful, honest frame for anyone wondering whether these drugs belong in their own care conversation.
⚠️ Why the GLP-1 eye warning matters here
As excitement about incretins in type 1 grows, a safety update landed that deserves attention. US FDA orders new eye risk warnings for Ozempic, Zepbound reports the FDA is requiring GLP-1 drugs, including Mounjaro, Zepbound, Ozempic, and Wegovy, to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition.
- CNN
A closer look from PharmExec notes the review found 15 probable NAION events in a meta-analysis (10 in GLP-1 users, 5 in placebo), and a retrospective cohort showed no significant increase versus SGLT-2 inhibitors (HR 1.19, 95% CI 0.91-1.54) but an increased risk versus DPP-4 inhibitors (HR 1.43, 95% CI 1.02-2.01). Per Ynet, the absolute risk works out to roughly 2.6 additional cases per 100,000 patient-years, and the FDA advises patients not to stop treatment without medical guidance.
The takeaway is proportion, not panic: the absolute risk is very low, but if you or someone you care for uses a GLP-1 and notices sudden vision changes, that is a same-day call to your clinician.
🔬 Screening, subtypes, and immune therapies worth tracking
The tirzepatide story is about managing established type 1. These items are about catching and slowing the disease earlier.
First UK patient receives teplizumab on NHS to delay type 1 diabetes describes a 42-year-old GP in Shropshire becoming the first to receive teplizumab through routine NHS care on 6 November 2026 to delay progression from stage 2. - The Diabetes Times. She put the value plainly: having "a little bit of breathing space before I need to start insulin" means time to prepare.
UF receives $5.5 million grant to evaluate drug that might slow Type 1 diabetes covers a Breakthrough T1D-funded trial of SAB-142, an experimental immune therapy for people 100 days to two years from a Stage 3 diagnosis, with a goal of learning which patients respond best. - UF Health.
FDA Approves TZIELD revisits the CD3-directed antibody shown to delay the decline in endogenous insulin production in children as young as eight.
Early Exocrine Pancreatic Biomarker Changes in Children at Risk of Type 1 Diabetes found, in the 301-child ENDIA cohort, that fecal elastase-1 was lower in the first 6 months of life among children who later developed autoantibodies or type 1 diabetes, while serum trypsin declined 12 to 18 months before diagnosis. - MedXY.
Adult Type 1 Diabetes Subtypes Reveal Different Risks used machine learning on 600 adults to identify three subtypes, with the mixed group modeled about 6.1 years earlier along the beta-cell decline trajectory, though the study did not show subtype-guided treatment improves outcomes. - EMJ.
🤰 Tools and devices making daily life easier
Advancing type 1 diabetes care during pregnancy: a Canadian first reports Health Canada approved Dexcom G7 for use with myLoop, powered by CamAPS FX, described as the only automated insulin delivery system in Canada approved specifically for pregnancy.
- Newswire / Ypsomed Canada
The approval leans on the AiDAPT trial, where CamAPS FX users spent 10.5 percentage points more time in the pregnancy-specific target range with no added hypoglycemia risk. The Globe and Mail adds a human layer, following a mother who delivered a healthy baby on Oct. 19 and credits her AID system, while clinicians stress pregnancy management remains "incredibly hard work."
A few more device and management updates worth a quick look:
The First Dual Glucose-Ketone Monitor is Approved in the U.S. covers Abbott's Libre Duo 10 Day, cleared for people aged two and up, which could help catch ketone trends tied to DKA earlier.
A new insulin patch pump system could reduce hypoglycaemia reports real-world data on the Kaleido pump with Diabeloop's DBLG1 and Dexcom G6 across 3,918 adults, showing a median time in range of 72.2% and median time below 54 mg/dL of 0.21%, about three minutes a day.
CeQur Simplicity Wearable Insulin Patch Now Available Nationally adds up to seven days of wear and 1-unit dosing; a CeQur/Harris poll of 409 adults found 51% miss or skip mealtime doses.
That last statistic is a quiet reminder of what all this research is ultimately for: making the relentless daily work of type 1 a little lighter. Thanks for reading, and take care of yourselves.